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Over the past two decades, 33 cases of colonic adenocarcinomas
have been diagnosed in rhesus macaques (Macaca mulatta) at the
nonhuman primate colony of the Keeling Center for Comparative
Medicine and Research at The University of Texas MD Anderson
Cancer Center. The distinctive feature in these cases, based on PET/
computed tomography (CT) imaging, was the presence of two or
three tumor lesions in different locations, including proximal to
the ileocecal juncture, proximal to the hepatic flexure, and/or in
the sigmoid colon. These colon carcinoma lesions selectively accu-
mulated [18F]fluorodeoxyglucose ([18F]FDG) and [18F]fluoroacetate
([18F]FACE) at high levels, reflecting elevated carbohydrate and
fatty acid metabolism in these tumors. In contrast, the accumula-
tion of [18F]fluorothymidine ([18F]FLT) was less significant, reflect-
ing slow proliferative activity in these tumors. The diagnoses of
colon carcinomas were confirmed by endoscopy. The expression of
MLH1, MSH2, and MSH6 proteins and the degree of microsatellite
instability (MSI) was assessed in colon carcinomas. The loss of
MLH1 protein expression was observed in all tumors and was
associated with a deletion mutation in the MLH1 promoter region
and/or multiple single-nucleotide polymorphism (SNP) mutations
in the MLH1 gene. All tumors exhibited various degrees of MSI.
The pedigree analysis of this rhesus macaque population revealed
several clusters of affected animals related to each other over
several generations, suggesting an autosomal dominant transmis-
sion of susceptibility for colon cancer. The newly discovered hered-
itary nonpolyposis colorectal cancer syndrome in rhesus macaques,
termed MLH1-rheMac, may serve as a model for development of
novel approaches to diagnosis and therapy of Lynch syndrome
in humans.
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Gastrointestinal cancers are the most common types of can-cers in aged nonhuman primates (1, 2) and account for 13%
of all tumors in macaques (3). In rhesus macaques (Macaca
mulatta), the incidence of intestinal adenocarcinomas increases
with age from 3.2% for animals aged 13–19 y to 20.7% for ani-
mals aged over 30 y (4). A recent study on the incidence of
spontaneous neoplasia in 2,660 captive rhesus macaques identi-
fied 217 with neoplastic diseases, among which gastrointestinal
system neoplasms were diagnosed in 48.8% of cases (5). The
colon and ileocecal junction are the most common locations for
carcinomas in macaques, with the cecum representing the ma-
jority of cases (1–12). Metastases are frequently observed in the
local and peripheral lymph nodes, liver, lungs, pancreas, and
adrenal glands in up to 34% of cases (12). However, the etiology
of colon carcinomas in rhesus macaques remains unclear. Po-
tential carcinogens in the diet have been suggested as a contrib-
uting factor (11), which is unlikely because of a controlled diet, a
relatively low-stress environment, lack of exposure to known car-
cinogens, and good veterinary care of macaques housed in academic
research centers. Infectious causes and various genetic mutations
causing spontaneous colon carcinomas in rhesus macaques have
also been suggested (12). Here, we reveal the existence of heredi-
tary nonpolyposis colon cancer syndrome in a rhesus macaque
population, which is associated with multiple single-nucleotide
polymorphism (SNP) mutations in the MLH1 gene and a de-
letion mutation in its promoter region.
Significance
The discovery of MLH1-rheMac hereditary nonpolyposis co-
lorectal cancer syndrome in rhesus macaques (MLH1-rheMac
HNPCC), which is an orthologue of Lynch syndrome in humans,
is highly significant in the field of oncology. The hereditary
nature of this disease should allow for planned cross-breeding
of rhesus macaques to assess the effects of homozygous versus
heterozygous MLH1 gene mutations, as well as other comuta-
tions and environmental factors that may affect the develop-
ment of colon cancers. Also, theMLH1-rheMac HNPCC syndrome
in rhesus macaques can serve as an important model for de-
velopment of novel approaches to diagnosis and therapy of
Lynch syndrome in human patients.
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Results and Discussion
Over the past two decades, 33 cases of colonic adenocarcinomas
have been diagnosed in rhesus macaques (M. mulatta) at the
nonhuman primate colony of the Keeling Center for Compara-
tive Medicine and Research at The University of Texas MD
Anderson Cancer Center. This rhesus macaque colony was
founded in 1974 from 360 rhesus monkeys of Indian origin, of
which 133 were wild-caught and the other 227 were derived from
10 domestic breeding colonies. An additional 31 females were
introduced in 1980, and four males were introduced in 1985. The
colony was closed to further immigration in 1985 (13).
In 1997, the first case of a stenosing colon adenocarcinoma in
a female rhesus monkey from this colony was reported (10).
More recently, additional colon carcinoma cases in rhesus ma-
caques have been identified during routine PET/computed tomog-
raphy (CT) imaging studies for the assessment of pharmacokinetics,
biodistribution, metabolism, and radiation dosimetry of novel
imaging agents (14, 15). These colon carcinoma lesions selectively
accumulated [18F]fluorodeoxyglucose ([18F]FDG) and [18F]fluo-
roacetate ([18F]FACE) at high levels (Fig. 1 A–D and SI Appendix,
Figs. S1 and S2), reflecting elevated carbohydrate and fatty acid
metabolism in these tumors. Furthermore, [18F]FDG accumula-
tion was observed not only in tumors but also in the peritumoral
tissues, suggesting an inflammatory process. In contrast, the ac-
cumulation of [18F]fluorothymidine ([18F]FLT) was low (Fig. 1 E
and F), reflecting slow proliferative activity in these tumors. A
distinctive feature in these cases was the presence of two or three
tumor lesions in different locations, including proximal to the
ileocecal juncture, proximal to the hepatic flexure, and/or in the
sigmoid colon. The diagnoses of colon carcinomas were con-
firmed by endoscopic examination (Fig. 1G). These tumors
typically formed an annular or “napkin-ring” constriction of the
colon (SI Appendix, Fig. S1E), often with an ulcerated central
region and dilation of the colon proximal to the tumor (SI Ap-
pendix, Fig. S1G). Histopathological examination of resected tu-
mors revealed colonic adenocarcinomas with desmoplastic and
infiltrative features that penetrated the muscularis mucosae and
invaded the inner and outer muscular layers of the large intestinal
wall (SI Appendix, Fig. S3 A and B). In advanced cases, tumor
invasion into the mesenterium (SI Appendix, Fig. S3 C–E) and
mesenterial lymph nodes (SI Appendix, Fig. S3 F and G) was
observed.
The multifocal nature of these colon carcinomas and histo-
pathological features also resembled those observed in human
patients with Lynch syndrome (16, 17). Lynch syndrome is one of
the most common hereditary colorectal carcinoma syndromes in
humans, accounting for 1–4% of all colorectal cancers and about
10% of cases before the age of 50 y (18–20). In humans, Lynch
syndrome, or hereditary nonpolyposis colorectal cancer syn-
drome (HNPCC), is diagnosed with the Amsterdam criteria,
which include the following: histologically confirmed colon car-
cinomas must be observed in at least three relatives, including
one first-degree relative and one with diagnosis before the age
of 50 y; two successive generations must be involved, and fa-
milial adenomatous polyposis should be excluded (21–23). The
Bethesda guidelines for diagnosis of Lynch syndrome include an
additional assessment of microsatellite stability (24).
Germline mutations of four genes involved in DNA mismatch
repair (MMR) are associated with Lynch syndrome: MLH1,
MSH2, MSH6, and PMS2, with over 90% of cases attributed to
mutations in the MLH1 and MSH2 genes (25–31). The loss of
DNA MMR, increased microsatellite instability (MSI), and loss
of heterozygosity are contributing factors in the etiology of tu-
mors associated with HNPCC (32, 33). Analyses of MSI, along
with characterization of MMR gene mutations and immunohis-
tochemical analyses of their expression in tumors, are currently
used for the diagnosis of Lynch syndrome.
Therefore, we assessed the expression of MLH1, MSH2, and
MSH6 proteins and the degree of MSI in colon carcinomas
resected from the three recently diagnosed rhesus macaques. We
observed loss of MLH1 protein expression in tumor cells and a
significant decrease in MLH1 expression levels in tumor stromal
cells (Fig. 2). Also, a significant decrease of MLH1 expression
was observed in 41% (11 of 27 of cases) of the affected animals,
and the loss of MLH1 expression was observed in stromal tumor
cells and normal colon mucosa in 30% of the affected animals
(eight of 27 cases) (SI Appendix, Fig. S4). A retrospective analysis
of colon carcinomas from our pathology archive (paraffin-
embedded specimens) gave similar results; none of the tumors
expressed MLH1 protein in the tumor cells, and a significant
decrease or loss of MLH1 expression was observed in the stroma
and in normal colon mucosal epithelial cells in some cases. The
results of immunohistochemical analyses of MLH1, MSH2, and
MSH6 expression in colon carcinomas and normal colon in the
rhesus macaques included in this study is summarized in SI
Appendix, Table S1.
MSI is observed in about 15% of sporadic colorectal cancers
(34) and most HNPCC (18–20, 35). Multiple errors in repetitive
DNA sequences (microsatellites) result from a failure of the
DNA MMR system to edit errors made during DNA replication.
Based on eight microsatellite markers (six rhesus-specific dinu-
cleotides and two human mononucleotides) all tumors exhibited
an MSI phenotype. For samples J72 and J106, we found clear
instability for BAT-26 (SI Appendix, Fig. S5). Tumors from
J72 and J106 could be classified as microsatellite-unstable
Fig. 1. Twenty-year-old female rhesus monkey (J123) with colonic adenocarcinoma. [18F]FDG (A and B), [18F]FACE (C and D), and [18F]FLT (E and F) images were
obtained with PET (A, C, and E) and PET/CT (B, D, and F), demonstrating multifocal colon carcinoma (white arrows). White bars indicate the axial image plane. (G)
Endoscopic image of colon carcinoma (field: 5-cm diameter). (H) H&E-stained histological section shows an invasive cecal adenocarcinoma. (Magnification: 200×.)
Brammer et al. PNAS | March 13, 2018 | vol. 115 | no. 11 | 2807
M
ED
IC
A
L
SC
IE
N
CE
S
colorectal cancers. Analysis of 16 other confirmed adenocarci-
noma cases revealed that some tumors exhibit MSI (MSI-H) and
others exhibit low MSI (MSI-L), whereas some are stable (MSI-
S), as defined by Kurzawski et al. (36). A summary of MSI
markers in 12 selected tumors is shown in SI Appendix, Table S2.
The pedigree analysis of this rhesus macaque population
revealed several clusters of affected animals related to each
other over several generations, which suggested autosomal
dominant transmission of susceptibility for the development of
colon cancer (Fig. 3 and SI Appendix, Figs. S6–S9). All colon
carcinoma cases in this colony could be traced back to three
founding male rhesus monkeys. In particular, the largest cluster
of rhesus macaques with MLH1-negative colon carcinomas
(10 confirmed cases) could be traced back to one male (821i)
Fig. 2. Immunohistochemical staining for MLH1, MSH2, and MSH6 of tumor tissues obtained from the affected rhesus macaques. Individual animal iden-
tifiers are on the left side of each horizontal trio of histological images. (Magnification: 20×.)
Fig. 3. Pedigree analysis of this rhesus macaque population. Several clusters of affected animals are related to each other over several generations, which
suggests an autosomal dominant transmission of susceptibility for the development of colon cancer.
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(Fig. 3 and SI Appendix, Fig. S6 and S7). This founding member
of the colony fathered 57 first-generation offspring from 1977
until 1993. Two of the offspring with colon cancer (J123 and
J106) share the same SNP pattern and MLH1 promoter dele-
tion described above. The other eight macaques with cancer
were born into subsequent generations. Noteworthy, one animal
(J104) that developed small intestinal adenocarcinoma and
pancreatic carcinoma had a normal MLH1 promoter sequence
and only one SNP in common with J123, J106, and J072. Also, it
should be noted that not all of the offspring of 821i were kept in
the breeding colony, and the incidence of cancer in the other
47 animals is not known. According to the pedigree, animal J072,
which shares the same SNP pattern as J123 and J106 and the
promoter deletion, is part of another family (Fig. 3 and SI Ap-
pendix, Fig. S8). Other interesting observations in the 282A
lineage are as follows: J183 had loss of MLH1 and loss in
MSH2 in the majority of tumor cells; L787 had loss of
MLH1 and a marked decrease or loss in MSH2 in the majority of
tumor cells, as well as loss of MSH6 expression; J417 had loss
of MLH1 and a marked decrease or loss in MSH2 in tumor cells;
and J368 had loss of MLH1 (Fig. 3 and SI Appendix, Fig. S9).
Thus, there is a clear pattern of dominant transmission of sus-
ceptibility to cancer in several kindreds in this population of
rhesus macaques. The age at diagnosis of colon carcinomas in
these rhesus macaques was 17.9 ± 3.5 y, which is somewhat
earlier than the typical age (>20 y) reported for high incidence of
spontaneous colorectal carcinomas (4, 6, 7, 11, 12).
To identify the hereditary transmitted mutations causing the
loss of MLH1 protein expression or function, we sequenced the
entire MLH1 gene from tumor and blood-derived DNA in three
initially diagnosed animals and in their 14 progeny animals. Se-
quencing included the 1,600-bp fragment upstream of adenine–
thymine–guanine (ATG) trinucleotide sequences, covering the
putative promoter region, and all 19 exons and introns (a total of
88.6 Kbp) of the MLH1 gene sequence described in the rhesus
macaque genome (37). One non–tumor-bearing, nonrelated
animal served as a control. All DNA sequences were compared
with the rhesus monkey reference genome samples of NC_007859
(47,230 bp and 15 exons on rhesus chromosome 2 from 99,514,335–
99,561,565) and NW_001112905.1 (3,707 bp with four exons
from unlocalized chromosome 2 genomic scaffolds). Although the
NW_001112905 has not been previously mapped to rhesus chro-
mosome 2, our analysis demonstrated that it is homologous to the
human sequence spanning exons 15–19.
A total of 124 SNPs were identified, in which three were exonic
SNPs (in exons 12, 13, and 14) and the remaining SNPs were
within introns. The heterozygous exon 14 SNP (rheMac2:
2:99,516,382; hg19: 3:37,081,750; c.1632 G > A) is a synonymous
SNP present in only one nonaffected monkey, which served as a
normal control. The other two heterozygous exonic SNPs were
nonsynonymous (SI Appendix, Table S3). The SNP in exon 13 re-
sults in an amino acid change from arginine to glutamine (rhe-
Mac2: 2:99,528,228; hg19: 3:37,070,325; c.1460 G > A), and the
SNP in exon 12 results in an amino acid change from threonine to
proline (rheMac2: 2:99,531,241; hg19: 3:37,067,311; c.1222 A >
C). Previously, a mutation in the same c.1222 (c.1222_1223insT)
has been described to cause Lynch syndrome in humans (38). The
SNP in exon 13 has been reported twice in patients with colon
cancer in the Leiden Open Variation Database (www.lovd.nl/2.0/
index.php; nos. 1008137 and 0041020) resulting in an amino acid
substitution identical to that observed in the rhesus macaque.
Furthermore, a heterozygous deletion in the putative pro-
moter region of the MLH1 gene (rheMac2: 2:99,561,829–
99,561,830; hg19: ∼3:37,034,780; c.−258_259) was identified in
three parent monkeys and their progeny, but not in the normal
control monkey (SI Appendix, Table S4). It should be noted
that the human MLH1 promoter sequence (NM_000249.2), 5′
GA(TC)2TAA 3′, differs from the monkey MLH1 promoter
sequence [NC_007859 and L627 colonMLH1(+)], 5′ GA(TC)4TAA
3′. The deletion mutant Mlh1 promoter exhibited 76% weaker
transcriptional activity in comparison with the wild-type pro-
moter, as demonstrated by luciferase reporter assay (Fig. 4). This
heterozygous dinucleotide deletion is within the same region of
the MLH1 gene promoter which causes the loss of MLH1 gene
expression in humans upon hypermethylation (39, 40). This
MLH1 promoter region includes the DNA binding sequence of
the CDP-CR transcription factor, which interacts with CCAAT
boxes to facilitate transcription (41). Similarly, a single-nucleotide
substitution (−107C → G) in the MLH1 promoter found in co-
lorectal cancer populations has been shown to reduce transcrip-
tional activity (42). The mutation −42C > T in the promoter
region of the MLH1 gene, localized within a putative Myb pro-
tooncogene binding site, has been described in a Newfoundland
kindred, meeting the Amsterdam Criteria for Lynch syndrome
(or HNPCC) (43). The −93G > A mutation in the MLH1 gene
promoter also increases the risk of microsatellite-unstable co-
lorectal cancers (44). Hypermethylation of this MLH1 promoter
region, including the region corresponding to the nucleotide pair
deleted in monkeys, has been reported to cause Lynch syndrome
in humans (45). Functional inactivation of the MLH1 promoter
by hypermethylation was shown to cause an MSI phenotype
(46, 47) and to be associated with Lynch syndrome (48). It has
been suggested that when the functional allele of MLH1 is lost
as part of the loss of the heterozygosity process, only the mu-
tated copy remains, thereby significantly decreasing the amount
of functional MLH1 protein produced (45). Also, it has been
recently demonstrated that targeted genetic inactivation or
temozolomide-induced loss of MLH1 expression in colorectal
cancer, breast carcinoma, and pancreatic carcinoma leads to
persistent accumulation of secondary mutations and widening
of the tumor antigen spectrum, whereas the MLH1-proficient
cancer cells exhibit a stable mutational load and tumor antigen
spectrum over time (49). Therefore, we hypothesized that germline
Fig. 4. Deletion mutant MLH1 promoter exhibits 76% weaker transcrip-
tional activity in comparison to the wild-type promoter, as demonstrated by
a dual-luciferase reporter assay. The promoter-inducible Firefly luciferase
(Fluc) bioluminescence intensity has been normalized by constitutively
expressed Renilla luciferase (Rluc) bioluminescence intensity. ***P < 0.001.
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transmission of the deletion mutation in the MLH1 promoter
identified in this study may contribute, at least in part, to the low
level of MLH1 expression, which may lead to the development of
colon carcinomas in animals bearing this mutation.
Using DNA sequence analysis of the MLH1 promoter, we
demonstrated the presence of mutations in multiple generations
within the same family (e.g., from the 821i lineage: J106 het-
erozygous, 7-172 homozygous, and 8-173 heterozygous; from the
512C lineage: J72 heterozygous, H421 homozygous, and 3-192
also homozygous). Interestingly, two independent female ma-
caques (J491 and J317) are both carriers of the same mutation.
DNA analysis demonstrated that the male, J72, who is hetero-
zygous for the promoter mutation, generated progeny that were
homozygous for this mutation when mated with each of the fe-
males indicated above. This observation strengthens the sug-
gestion that the observed MLH1 mutation is a true germline
mutation causing the hereditary colorectal cancer syndrome in
rhesus macaques. Additional studies are required to determine
the relative frequency of these MLH1 mutations by DNA se-
quence analysis of blood samples obtained from other pop-
ulations of rhesus macaques.
Herewith, we propose a new terminology for distinguishing
this syndrome in rhesus monkeys from the Lynch syndrome
known in humans. The new term defining this HNPCC syndrome
in rhesus macaques should consist of the name of the gene that is
mutated followed by “-rheMac,” which is the same acronym that
is used for the rhesus monkey genome assembly. For example,
the current 33 cases of colon cancer that do not express
MLH1 would be defined as the MLH1-rheMac syndrome. The
nomenclature system can be expanded in the future: As rhesus
monkeys are identified with MSH2, MSH6, and PMS2, their
syndrome can be identified as MSH2-rheMac, MSH6-rheMac,
and PMS2-rheMac.
Screening methods described in this study provide an oppor-
tunity for a number of additional studies related to MLH1 and
colon cancer. Further analyses can address other known char-
acteristics of MLH1 defects, such as endometriosis, and cancers
of the endometrium, ovary, urinary tract, stomach, small bowel,
biliary tract, and brain. The identification of breeding-age rhesus
monkeys with MLH1, MSH2, and MSH6 deficiencies could lead
to the establishment of a breeding colony with defined DNA
MMR gene deficiencies.
In summary, current results provide supportive evidence for
the existence of HNPCC (MLH1-rheMac syndrome) in rhesus
macaques resulting from the loss of MLH1 protein expression,
which represents a simian ortholog of Lynch syndrome in hu-
mans. The loss of MLH1 expression is potentially due to several
reasons, including a deletion mutation in the MLH1 promoter
region, which results in decreased transcriptional activity. Also,
several SNPs in the MLH1 gene were associated with MLH1-
rheMac syndrome in rhesus macaques. Although similar SNPs
have been shown to cause Lynch syndrome in humans, we cannot
definitively state at this time that these SNPs cause the MLH1-
rheMac syndrome in rhesus macaques. Additional studies of
functional consequences of these SNPs in the MLH1 gene are
pertinent, as well as systematic genetic screening of different
colonies of rhesus macaques to identify animals carrying the
observed mutations in the MLH1 gene, which may have de-
veloped or may develop colon carcinomas. Furthermore, rhesus
macaques with MLH1-rheMac syndrome may provide an im-
portant resource for studies of the pathogenesis of the colon
carcinomas under controlled conditions, including studies of
environmental and other factors that may interact with genetic
risk factors that may influence the onset and progression of colon
carcinomas and other cancers associated with Lynch syndrome,
as well as for evaluation of novel drugs and diagnostic agents that
may improve the outcome of treatment of Lynch syndrome in
human patients.
Methods
PET/CT Imaging. The animals were premedicated with 0.04 mg/kg i.m. atro-
pine sulfate and sedated with 10–15 mg/kg i.m. ketamine, followed by in-
tubation and inhalation anesthesia with 1–3% isoflurane in oxygen via Excel
210 SE (Ohmeda). PET/CT imaging studies were performed with Discovery
STE16 (GE Healthcare) at 1 h after i.v. administration of [18F]FDG (8 mCi) or
[18F]FACE (8 mCi), or 3′-[18F]FLT (8 mCi). PET/CT imaging studies with each
radiotracer were performed on different days, all within a period of 3 wk.
The details of PET/CT image acquisition and processing are provided else-
where (14, 15).
Endoscopy. Bowel preparation began 2 d before inoculation. On the first day,
the feedwas restricted to one portion of food in themorning, mixedwith five
tablets of sodium phosphate (Visicol) to help empty the rectum. Next day, a
polyethylene glycol 3350 solution (30 mL/kg; NuLYTELY) with electrolyte
solution was employed as a bowel-cleansing agent, and the animals were
fasted overnight. The animals were premedicated with 0.04 mg/kg i.m. at-
ropine sulfate and sedated with 10–15 mg/kg i.m. ketamine, followed by
intubation and inhalation anesthesia with 1–3% isoflurane in oxygen via
Excel 210 SE. Endosopic examination was performed with the animal in the
left lateral position using a standard endoscope (GIF-H180; Olympus
America, Inc.).
Immunohistochemistry. Immunohistochemistry was performed in paraffin-
embedded tumor tissue sections and normal colon samples from newly di-
agnosed animals (necropsy material). Five-micrometer sections of tumor tissue
were mounted on Superfrost/Plus microscope slides (catalog no. 12-550-15;
Fisher). Antigen retrievalwasperformedbymicrowave heating in sodium citrate
buffer (pH 6.0) for 10min. Slideswere then incubated in 3%H2O2 for 15min and
blocked with 2% normal horse serum (ABC kit, PK-6102; Vector Laboratories)
for 1 h. The slides were incubated with mouse monoclonal antibodies to MLH1
(1:100) (51-1327GR; BD Pharmingen), to MSH2 (1:100) (NA27; Calbiochem), and
to MSH6 (1:200) (610918; BD Transduction laboratories) at 4 °C overnight.
Biotinylated anti-mouse IgG was used as a secondary antibody at a 1:200 di-
lution (BA-2000; Vector) for 30 min. The chromogen was 3,3-diaminobenzidine,
and counterstaining was performed with hematoxylin. Photomicrographs of
stained tissue sections were obtained with a BX51 microscope (Olympus).
MSI. In total, 12 formalin-fixed, paraffin-embedded (FFPE) tumor samples
(representing 12 monkeys) were analyzed for MSI. Of these, eight were
obtained by manual dissection and four were obtained by laser capture
microdissection (LCM). Normal tissue (i.e., liver, kidney) was also collected
from FFPE blocks from seven monkeys. These seven normal/tumor pairs were
analyzed forMSI with humanmononucleotides and rhesus dinucleotides. The
other five tumor samples were analyzed with only human mononucleotides.
LCM was performed with a PixCell II system (Arcturus Engineering, Inc.) as
described elsewhere (50). Briefly, slides were stained with hematoxylin and
eosin, examined under a light microscope, and microdissected. Samples were
purified with a fixed-tissue genomic DNA purification kit (Promega).
For the MSI screening, we used eight markers, adapted from the National
Cancer Institute recommendations (24, 33). Human intragenic microsatellites
BAT-25 and BAT-26 were selected as the only mononucleotide markers with
which to study microsatellite status in tumors from rhesus macaques. We
redesigned and tested new primers based on comparative DNA sequence
analysis of rhesus and human KIT (BAT-25) and MSH2 (BAT-26) genes. Being
quasimonomorphic in the human population, these markers circumvent the
need for normal tissue (24). Since our attempts to amplify rhesus DNA with
human dinucleotide markers from the Bethesda panel failed, we selected a
set of six dinucleotides microsatellites previously described for rhesus ma-
caques (51): MML3S7, MML4S1, MML11S1, MML16S3, MML17S2, and
MML18S3. Markers were PCR-amplified with fluorescently labeled primers
(6FAM, VIC, or NED; Applied Biosystems) as described elsewhere (52). The
PCR amplifications were performed with Eppendorf MasterCycler Gradient
(Eppendorf). Samples were loaded in a 96-well plate, denatured at 95 °C for
5 min, and analyzed by capillary electrophoresis in an ABI Prism 3130XL in-
strument (Applied Biosystems) with POP4 polymer (Applied Biosystems). The
alleles were visualized and scored with GenMapper software v.4.0 (Applied
Biosystems). The degree of instability in the tumor samples was scored
according to the percentage of the eight markers showing allele shifts as
stable (MSI-S, no markers showing instability), low (MSI-L, one to two
markers showing instability), or high (MSI-H, more than three markers
showing instability). All samples showing allele shifts were studied twice.
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DNA Sequencing. We resequenced the MLH1 gene (including ∼1,600 bp 5′ to
exon 1) in affected and unaffected macaques. The DNA samples included the
L627 control, which expresses MLH1 in the colon, as well as J123, J106, and J72
(MLH1-negative) and 12 offspring of J106 and J72. DNA was extracted from
white blood cells or liver samples by standard phenol/chloroform methods. The
humanMLH1 has 19 exons and the rhesus reference (rhemac2) has exons 1–15.
The remaining four exons are in rhesus unlocalized scaffold NW_001112905.1,
which is not mapped to rhemac2. We used both reference and unmapped
rhesus scaffold sequences to design primers to amplify the full segments (exons
1–19, promoter, UTRs, and introns) of the rhesus MLH1gene. The full set of
primers for rhesus macaqueMHL1 gene sequencing is listed in Table S5. We used
Sanger sequencing, and the SNP Detector 3.0 program (53) was used to identify
SNPs, insertions, and deletions in the MLH1 gene region. The mutations on
the MLH1 gene region were annotated based on the Ensembl database
(www.ensembl.org/) with two rhesus transcripts (ENSMMUT00000031714
with 15 exons and ENSMMUT00000031713 with 10 exons). The mutations on
the unmapped rhesus scaffold were not annotated.
Pedigree Analysis. The pedigree analysis was performed with archival records
ofmating and births in the colony and diseased animal records. The datawere
analyzed using Cyrillic v.3 software (AP Benson, Ltd.).
More information about the MLH1 promoter activity assay is provided in
SI Appendix.
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